Commenting on the final decision, Barry Siegel of Washington University said, "Speaking on behalf of the entire NOPR Working Work, I am gratified at the culmination of our 7-year effort to obtain broader coverage for FDG-PET. The success of our foray into Coverage with Evidence Development speaks to a strong collaborative relationship with CMS, and we greatly appreciate CMS' responsiveness to the community's input in formulation of the final decision. My only regret is that our colleague Ed Coleman was not able to share this important event with us."
Professor Ed Coleman, a well-recognized PET advocate passed away in 2012.
In the final decision CMS also expanded the number of covered scans for subsequent treatment strategy to three scans and has indicated covering prostate. Dr. Steve Larson of Memorial Sloan-Kettering Cancer Center said "My colleagues and I are very pleased that FDG-PET is recognized by CMS for use in prostate cancer based on the peer reviewed literature and evidence. I think it says something good about the process that despite an initial proposed "non-coverage", upon re-review with additional data, CMS decided that PET FDG was reasonable and necessary for patients with progressing prostate cancer. CMS is to be commended for putting in place a review that was both thorough and fair."
Please note that this decision applies to the FDG-PET registry (NOPR-2009) only. The NaF-PET registry run jointly by ACR-WMIS will continue to collect additional data.
The World Molecular Imaging Society (WMIS
Copyright©2012 Vocus, Inc.
All rights reserved